Humilis Investments' Brian Belski launches HIS, a new ETF
Gilead Sciences, Inc GILD
$130.50
▲ +0.64%
(+$0.83)
Index member:
S&P 500
NASDAQ-100
Open
$129.50
Prev Close
$129.67
Day Range
$128.34 – $132.34
52W Range
$100.23 – $157.29
Market Cap
$167.54B
P/E (TTM)
17.64
Beta
0.33
Div Yield
2.53%
EPS (TTM)
$7.35
📋 Company Profile
| Industry | Biotechnology |
| Sector | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1992-01-22 |
| Shares Out. | 1,241,220,000 |
| Website | gilead.com ↗ |
| Phone | 13026587581 |
Gilead Sciences, Inc is a publicly traded company under the ticker symbol GILD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
39 analysts (2026-05-01)
📰 Latest News for GILD
Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
3 Market-Beating Stocks to Research Further
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion